OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OPRX OptimizeRx Corporation

Trading 03-28 13:20:38 EDT

8.43

-0.31

-3.55%

High8.91	Low8.34	Vol98.43K
Open8.73	D1 Closing8.74	Amplitude6.58%
Mkt Cap155.87M	Tradable Cap120.35M	Total Shares18.49M
T/O835.80K	T/O Rate0.69%	Tradable Shares14.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"OPRX","market":"US","secType":"STK","nameCN":"OptimizeRx Corporation","latestPrice":8.43,"timestamp":1743182426797,"preClose":8.74,"halted":0,"volume":98431,"delay":0,"floatShares":14276520,"shares":18490385,"eps":-1.1,"marketStatus":"Trading","change":-0.31,"latestTime":"03-28 13:20:38 EDT","open":8.73,"high":8.91,"low":8.335,"amount":835796.519752,"amplitude":0.065789,"askPrice":8.43,"askSize":250,"bidPrice":8.38,"bidSize":2101,"shortable":3,"etf":0,"ttmEps":-1.1,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":8.74,"preHourTrading":{"tag":"盘前","latestPrice":8.98,"preClose":8.74,"latestTime":"06:15 EDT","volume":1,"amount":8.98,"timestamp":1743156931979},"postHourTrading":{"tag":"盘后","latestPrice":8.74,"preClose":8.74,"latestTime":"19:57 EDT","volume":1696,"amount":14821.2112,"timestamp":1743119852824},"volumeRatio":0.576133,"impliedVol":0.8528,"impliedVolPercentile":0.652},"requestUrl":"/m/hq/s/OPRX","defaultTab":"news","newsList":[{"id":"2519388077","title":"OptimizeRx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2519388077","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519388077?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:48","pubTimestamp":1741862934,"startTime":"0","endTime":"0","summary":"NasdaqCM:OPRX Earnings and Revenue Growth March 13th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 2.2%. Earnings per share  missed analyst estimates by 5.2%.Looking ahead, revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US.The company's shares are up 25% from a week ago.It's necessary to consider the ever-present spectre of investment risk.   We've identified 3 warning signs  with OptimizeRx , and understanding them should be part of your investment process.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-full-2024-earnings-revenues-104854164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2519619003","title":"OptimizeRx Corp (OPRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Margin Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2519619003","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519619003?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 15:03","pubTimestamp":1741849388,"startTime":"0","endTime":"0","summary":"Fourth Quarter Revenue: $32.3 million, up 14% from $28.4 million in Q4 2023.Gross Margin: Increased to 68.2% in Q4 2024 from 62.9% in Q4 2023.Operating Expenses: Decreased by $10.4 million year-over-year in Q4 2024.Net Loss: $0.1 million in Q4 2024, compared to $4.1 million in Q4 2023.Non-GAAP Net Income: $5.5 million or $0.30 per diluted share in Q4 2024.Adjusted EBITDA for Q4: $8.8 million, up from $5.8 million in Q4 2023.Cash and Short-term Investments: $13.4 million as of December 31, 2024.Debt Balance: $34.3 million after paying off $2.5 million of principal in Q4 2024.Average Revenue for Top 20 Pharmaceutical Manufacturers: $2.9 million, a 22% increase year-over-year.Net Revenue Retention Rate: 121%, up from 105% in the prior period.Revenue per FTE: $701,000, up from $586,000 in the prior year.GuruFocus has detected 3 Warning Signs with OPRX.For the complete transcript of the earnings call, please refer to the full earnings call transcript.OptimizeRx Corp  exceeded its 2024 finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-corp-oprx-q4-2024-070308859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2519072613","title":"Q4 2024 OptimizeRx Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2519072613","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519072613?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 13:25","pubTimestamp":1741843529,"startTime":"0","endTime":"0","summary":"Stephen Silvestro; President, Chief Executive Officer; OPTIMIZERx Corp. Edward Stelmakh; Chief Financial Officer, Chief Operating Officer; OPTIMIZERx Corp. Andrew D'Silva; Senior VP of Corporate Finance; OPTIMIZERx Corp. Jared Haase; Analyst; William Blair & Company L.L.C.Eric Martinuzzi; Analyst; Lake Street Capital Markets, LLC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-optimizerx-corp-earnings-052529278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2518969748","title":"OptimizeRx confirems receipt of notice of director nominations","url":"https://stock-news.laohu8.com/highlight/detail?id=2518969748","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518969748?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:41","pubTimestamp":1741693280,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, regarding its intention to nominat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-confirems-receipt-of-notice-of-director-nominations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-confirems-receipt-of-notice-of-director-nominations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2518771740","title":"Press Release: OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations","url":"https://stock-news.laohu8.com/highlight/detail?id=2518771740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518771740?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 19:30","pubTimestamp":1741692600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March 11, 2025  -- OptimizeRx Corp.  , a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals  and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2025 Annual Meeting of Stockholders, which has not yet been scheduled.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2518895467","title":"Whetstone Capital Advisors Says Intends Nominate Andrew Carlson and John Fein for Election to OptimizeRx Corp's Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2518895467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518895467?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 05:40","pubTimestamp":1741642813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0RJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2518789549","title":"Whetstone Capital Advisors Says on March 6, Provided Written Notice to OptimizeRx Corp - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518789549?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 05:40","pubTimestamp":1741642813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2518737412","title":"Lake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518737412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518737412?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 22:35","pubTimestamp":1741617353,"startTime":"0","endTime":"0","summary":"Lake Street analyst Eric Martinuzzi maintained a Buy rating on OptimizeRx (OPRX – Research Report) today and set a price target of $11.00. The comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-reaffirms-their-buy-rating-on-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX"],"gpt_icon":0},{"id":"2518222540","title":"OptimizeRx Corp  expected to post earnings of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518222540?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 20:35","pubTimestamp":1741610117,"startTime":"0","endTime":"0","summary":"OptimizeRx Corp  expected to post earnings of27cents a share - Earnings Preview OptimizeRx Corp OPRX.OQ OPRX.O is expected to show a rise in quarterly revenue when it reports  results on March 12 for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0},{"id":"2518240646","title":"BRIEF-OPTIMIZERx appoints Stephen Silvestro as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240646","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240646?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:42","pubTimestamp":1741606958,"startTime":"0","endTime":"0","summary":"BRIEF-OPTIMIZERx appoints Stephen Silvestro as CEOMarch 10 (Reuters) - OPTIMIZERx Corp OPRX.O:OPTIMIZERX CORPORATION APPOINTS STEPHEN SILVESTRO AS CHIEF EXECUTIVE OFFICERSource text: ID:nGNX5wx94BFurther company coverage: OPRX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA8XGG2T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2518240350","title":"OptimizeRx appoints Silvestro as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240350","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240350?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:35","pubTimestamp":1741606544,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) announced it has appointed Steve Silvestro as the Company’s new Chief Executive Officer, effective March 10, 2025. Silvestro brin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-appoints-silvestro-as-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-appoints-silvestro-as-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2518324711","title":"OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518324711","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518324711?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:30","pubTimestamp":1741606200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA8XGG2T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2518247182","title":"Press Release: OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247182","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247182?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:30","pubTimestamp":1741606200,"startTime":"0","endTime":"0","summary":"Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team. \"I am honored to have the Board's trust and to have the opportunity to lead the next phase of OptimizeRx's growth and transformation. We will continue to differentiate ourselves within the market through our technology and by developing more meaningful strategic partnerships with our customers. Now more than ever, we will be laser-focused on operational excellence while ensuring we delight our customers and forge stronger relationships with valued business partners,\" added Steve Silvestro. \"Since the time I was asked to take the helm in December, we have completed an extensive strategic review of the Company's business processes, operations, and opportunities for shareholder value creation. I look forward to collaborating with our Board, team members, strategic partners, and customers as we continue the Company's growth, focusing very closely on customer ce","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","OPRX","BK4232","BK4022","BK4167"],"gpt_icon":0},{"id":"2518428504","title":"We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2518428504","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518428504?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 22:22","pubTimestamp":1741443768,"startTime":"0","endTime":"0","summary":"David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-oprx/optimizerx/news/we-think-optimizerx-nasdaqoprx-has-a-fair-chunk-of-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","BK4585","PSQ","NVIW.SI","IE00B64PRP62.GBP","BK4588","QLD","BK4112","TSYW.SI","OPRX","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4167","IE00BKPKM429.USD",".IXIC","USAW.SI","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","MNQmain","TQQQ","NDAQ","QID","SQQQ","USJW.SI"],"gpt_icon":1},{"id":"2517902059","title":"What Does OptimizeRx Corporation's (NASDAQ:OPRX) Share Price Indicate?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517902059","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517902059?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 18:50","pubTimestamp":1741171822,"startTime":"0","endTime":"0","summary":"While OptimizeRx Corporation  might not have the largest market cap around , it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQCM. While good news for shareholders, the company has traded much higher in the past year. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy?Let’s take a look at OptimizeRx’s outlook and value based on the most recent financial data to see if the opportunity still exists.If you are no longer interested in OptimizeRx, you can use our free platform to see our li","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/does-optimizerx-corporations-nasdaq-oprx-105022888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","QID","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","TSYW.SI","LU2095319765.USD","BK4167","LU2210149790.SGD",".IXIC","MNQmain","IE00B3QW5Z07.USD","TQQQ","OPRX","NQmain","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","USAW.SI","BK4588","PSQ","SQQQ","IE00BKPKM429.USD","BK4112","QLD"],"gpt_icon":1},{"id":"2510726321","title":"One OptimizeRx Insider Raised Their Stake In The Previous Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2510726321","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510726321?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 18:22","pubTimestamp":1739355748,"startTime":"0","endTime":"0","summary":"Viewing insider transactions for OptimizeRx Corporation's  over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.The Last 12 Months Of Insider Transactions At OptimizeRx. The insider William Febbo made the biggest insider purchase in the last 12 months. That single transaction was for US$100k worth of shares at a price of US$5.01 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$5.60. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulator","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/one-optimizerx-insider-raised-stake-102228013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2509783237","title":"Whetstone Capital Discloses 8.2% Stake in OptimizeRx, Urges Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2509783237","media":"GuruFocus.com","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509783237?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 02:36","pubTimestamp":1738780578,"startTime":"0","endTime":"0","summary":"Whetstone Capital Advisors disclosed an 8.2% stake in OptimizeRx , according to a Schedule 13D filing with the Securities and Exchange Commission.GuruFocus has detected 3 Warning Signs with OPRX.Under David Atterbury's direction, the Kansas-based investment company declared ownership of about 1.51 million OptimizeRx common stock with a total acquisition price of $7.56 million .A letter Whetstone wrote to OptimizeRx's Board of Directors on Feb. 3, encouraging the firm to investigate strategic options including a potential sale of the business, set off the Feb. 5 filing. Whetstone said he thinks the stock of the firm is underpriced and that a sale or reorganization may optimize shareholder profits.Serving private funds with OptimizeRx stock, Whetstone Capital acts as an investment adviser and has the right to direct voting and share distribution. According to the 13D filing of the business, it will interact with the leadership, fellow investors, and possible industry partners or rivals o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whetstone-capital-discloses-8-2-183618603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2503482314","title":"OptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2503482314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503482314?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 09:38","pubTimestamp":1736732282,"startTime":"0","endTime":"0","summary":"In a report released on January 10, David Grossman from Stifel Nicolaus downgraded OptimizeRx (OPRX – Research Report) to a Hold, with a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimizerx-oprx-was-downgraded-to-a-hold-rating-at-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimizerx-oprx-was-downgraded-to-a-hold-rating-at-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","OPRX"],"gpt_icon":0},{"id":"2501472022","title":"OptimizeRx downgraded to \"sector perform\" by RBC amid slower growth outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2501472022","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501472022?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 21:37","pubTimestamp":1736343454,"startTime":"0","endTime":"0","summary":"Investing.com -- RBC Capital Markets has downgraded OptimizeRx Corp  to \"sector perform,\" reflecting a tempered outlook on the company's growth prospects.RBC analysts cited challenges in the company's direct-to-consumer segment, particularly as clients transition to a self-service model that generates lower revenue but offers higher margins.This shift, coupled with weaker bookings attributed to the timing of the Medicx acquisition in late 2023, is expected to dampen revenue growth through the first half of 2025.OptimizeRx's updated revenue projections for 2025 have been revised downward to $94 million, reflecting a modest 2.7% growth compared to an earlier forecast of 11%.This adjustment aligns with RBC's recalibrated EBITDA estimate, now at $10.4 million for 2025, reflecting subdued growth expectations. Consequently, RBC has also lowered its price target for the stock to $6 from $7.The company's challenges in the DTC business are partly offset by growth in its healthcare provider-focu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-downgraded-sector-perform-rbc-133734680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2501729112","title":"OptimizeRx Cut to Sector Perform From Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2501729112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501729112?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 20:46","pubTimestamp":1736340360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 07:46 ET (12:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.optimizerx.com","stockEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":0.646},{"period":"3month","weight":0.7171},{"period":"6month","weight":0.1277},{"period":"1year","weight":-0.2807},{"period":"ytd","weight":0.7984}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.067108},{"month":2,"riseRate":0.571429,"avgChangeRate":0.038318},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.000778},{"month":4,"riseRate":0.5,"avgChangeRate":-0.074092},{"month":5,"riseRate":0.5,"avgChangeRate":0.099038},{"month":6,"riseRate":0.833333,"avgChangeRate":0.062928},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.02887},{"month":8,"riseRate":0.571429,"avgChangeRate":0.002178},{"month":9,"riseRate":0.428571,"avgChangeRate":0.056563},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.051657},{"month":11,"riseRate":0.571429,"avgChangeRate":0.059021},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.005062}],"exchange":"NASDAQ","name":"OptimizeRx Corporation","nameEN":"OptimizeRx Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OptimizeRx Corporation,OPRX,OptimizeRx Corporation股票,OptimizeRx Corporation股票老虎,OptimizeRx Corporation股票老虎国际,OptimizeRx Corporation行情,OptimizeRx Corporation股票行情,OptimizeRx Corporation股价,OptimizeRx Corporation股市,OptimizeRx Corporation股票价格,OptimizeRx Corporation股票交易,OptimizeRx Corporation股票购买,OptimizeRx Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction